Can-Fite BioPharma annual r&d spending
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Can-Fite BioPharma R&D Spending Growth & History (CANF)
Can-Fite BioPharma's r&d spending was $6.7M for fiscal 2025.
View full Can-Fite BioPharma company overviewCan-Fite BioPharma annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.7M | $936,000 | +16.26% |
| 2024 | 2024-12-31 | $5.8M | −$226,000 | −3.78% |
| 2023 | 2023-12-31 | $6.0M | $5.8M | +4267.15% |
| 2022 | 2022-12-31 | $137,000 | −$63,000 | −31.50% |
| 2021 | 2021-12-31 | $200,000 | $41,000 | +25.79% |
| 2020 | 2020-12-31 | $159,000 | $21,000 | +15.22% |
| 2019 | 2019-12-31 | $138,000 | $15,000 | +12.20% |
| 2018 | 2018-12-31 | $123,000 | −$5.0M | −97.59% |
| 2017 | 2017-12-31 | $5.1M | −$1.0M | −16.50% |
| 2016 | 2016-12-31 | $6.1M | — | — |
Can-Fite BioPharma r&d spending trends
Over the last five fiscal years, Can-Fite BioPharma's r&d spending increased from $159,000 to $6.7M, a change of $6.5M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Can-Fite BioPharma source filings ↗